Research Research Research Programs Systems, Pathways & Targets Biotechnology, Imaging & Drug Development Cancer Control Clinical Research Disease-Oriented Teams Stern Center for Cancer Clinical Trials and Research Research Resources Shared Resources Funding Opportunities Membership Guidelines Acknowledgement of Shared Resources Centers & Institutes Anti-Cancer Challenge Research Anti-Cancer Challenge RFP Team Funds Anti-Cancer Challenge Past Awardees Anti-Cancer Challenge RFP Home Research UCI Anti Cancer Challenge Research Anti Cancer Challenge RFP 2020 Tracks and Focus Areas This Request for Proposal submission closed on January 19, 2021. This competition will provide up to 15 awards of up to $40,000 each (direct costs) along two tracks, with a specific emphasis on projects capable of significant impact within 1-2 years: Track 1 projects are standard 1-year basic or translational pilot project proposals, with an endpoint of a competitive peer-reviewed extramural grant application. Projects to acquire key preliminary data for a planned submission/resubmission of a peer-reviewed extramural grant, especially to NCI. Special consideration is to applications supporting resubmissions that generate new data in response to prior critiques. Track 2 projects are Early Phase Clinical Research project proposals, with an endpoint of an interventional investigator-initiated treatment trial at UC Irvine Health within a 2-year time frame. Trials must be managed by the Stern Center for Cancer Clinical Trials & Research. Projects must be initiated from a Disease-Oriented Team or a multidisciplinary tumor board, must include a DOT-approved clinical protocol and should have full regulatory approval within 6 months of award. While Track 2 projects are not necessarily expected to lead to extramural peer-reviewed funding, pharmaceutical industry co-sponsorship is encouraged. The following FOCUS AREAS will be especially competitive: Research addressing health disparities1 in the Cancer Center’s Catchment Area of Orange County. This includes: Cancers with unusually high incidence or prevalence in the catchment area, such as melanoma, breast and lung cancer Cancers disproportionately affecting racial or ethnic groups, such as liver and gastric cancer in Hispanics and Asians, cervical, gall bladder, and young onset colorectal cancer in Hispanics Projects addressing unique aspects of a specific cancer burden in the catchment area (e.g., etiology of lung adenocarcinoma in Asian female never-smokers or of Ph-like B-lymphoblastic leukemia in Hispanics; basis for low HPV vaccination rates in different racial/ethnic groups; melanoma detection/prognosis in Hispanics) Projects addressing research questions in population health and cancer control (etiology and/or prevention) relevant to the catchment area, particularly involving collaborations between Cancer Control Program members & other CFCCC Programs Projects addressing cancers of relevance to pediatric/AYA populations Collaborations involving Disease-Oriented Teams or multidisciplinary tumor boards that seek to advance a novel diagnostic or screening technology, therapeutic molecule or device, or bio-behavioral intervention to a clinical trial Projects leveraging CFCCC Shared Resources Applications from Early Stage Investigators 1 The NCI defines cancer health disparities as “adverse differences in cancer incidence (new cases), cancer prevalence (existing cases), cancer death (mortality), cancer survivorship, and burden of cancer related conditions that exist among specific population groups in the United States.” 2020 Application Guidelines Eligibility UCI researchers eligible to serve as principal investigator on a research grant (e.g., faculty or project scientist) and CHOC Hyundai Cancer Institute-affiliated physicians are eligible to apply. CFCCC membership must be established by the time of award. Each PI may submit only one application. Selection Criteria Applications will be peer reviewed in accord with NIH criteria with explicit emphasis placed on the near-term impact (i.e., within 1-2 years). Projects from clinical researchers and basic science investigators that extend their studies to clinical or translational research are strongly encouraged, as are applications from early stage investigators and investigators whose projects use CFCCC Shared Resources or involve significant new collaborations. Regulatory Approvals Proposals with a clinical component must have an existing regulatory approval (e.g. human subjects or animal protocol that is either IRB/IACUC-approved) or ready for IRB/IACUC submission (i.e., DOT-approved). If sufficient progress in obtaining regulatory approvals has not been made within 6 months after award date, the CFCCC may withdraw the award. Budget and Reporting Exclusions: Faculty salaries, large equipment (e.g., >$5K), travel, and indirect costs are not allowed. Plan to fully spend the award within 1 year for Track 1 projects and within 2 years for Track 2 projects. A final report is due within 30 days of completing the project. Awardees may be asked to present a 15-20 minute “chalk talk” to a peer-colleague committee for feedback on progress. A single no-cost extension, for up to 6 months, will be considered for review by the Center Administrator and presentation to Cancer Center leadership for final determination. Letter of Intent Applicants must use the provided template and naming convention Lastname_ACC LOI_YYYY-MM-DD (e.g., Smith_ACC LOI_2020-12-07), and email to CFCCC Administration at email@example.com. The LOI is required for assignment of peer reviewers for full proposal submission and will not be reviewed for competition. Therefore, applicants should proceed with their full proposal after submitting the LOI. The LOI should include: Application track (1 or 2) and Project Title Key Personnel - Names, academic ranks, department affiliation and email address of the contact Principal Investigator and other Key Personnel Abstract - One paragraph abstract/introduction about background, significance, and impact of the research Specific Aims Application Format Applicants must submit the attached CFCCC Pilot Project Application form (template attached). The application should state clearly why funding through this pilot grant mechanism is appropriate and should outline the specific plans for extramural grant submissions (Track 1 projects) or for launching an investigator-initiated treatment trial (Track 2 projects). Completed applications will include: Cover page with requested project information, a scientific abstract (NIH format) and a lay abstract (3-4 sentences). Project Description (3 pages maximum) including the Background and Significance, Research Plan and Specific Aims, and the rationale for requested funds with specific plans for extramural grant submissions or investigator-initiated treatment trials. References cited. Budget and budget Justification (1 page each). Include an NIH Biosketch listing your current sources of funding and a one-line description of the primary goal of each funded grant. A biosketch should be included for each key personnel involved with the project. Applications must adhere to the following formatting requirements: Arial font; 11 pt.; minimum 0.5 inch for all margins; no appendices. Application Submission The application should be submitted via email as one complete pdf file named Lastname_ACC Application_YYYY-MM-DD (e.g., Smith ACC Application_2021-01-18) to CFCCC Administration at firstname.lastname@example.org. Receipt of all applications will be acknowledged within 2 business days. For inquiries regarding this request for proposals, please contact CFCCC Administration at email@example.com.